In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...
MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. | AstraZeneca is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results